BRPI0417268A - benzimidazóis que contêm morfolinila, como inibidores da replicação de vìrus sinciciais respiratórios - Google Patents
benzimidazóis que contêm morfolinila, como inibidores da replicação de vìrus sinciciais respiratóriosInfo
- Publication number
- BRPI0417268A BRPI0417268A BRPI0417268-0A BRPI0417268A BRPI0417268A BR PI0417268 A BRPI0417268 A BR PI0417268A BR PI0417268 A BRPI0417268 A BR PI0417268A BR PI0417268 A BRPI0417268 A BR PI0417268A
- Authority
- BR
- Brazil
- Prior art keywords
- hydrogen
- respiratory syncytial
- substituted
- alkyloxy
- morpholinyl
- Prior art date
Links
- 241000725643 Respiratory syncytial virus Species 0.000 title abstract 3
- 125000002757 morpholinyl group Chemical group 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000029812 viral genome replication Effects 0.000 title abstract 2
- 150000001556 benzimidazoles Chemical class 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 150000002431 hydrogen Chemical group 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- -1 homopiperidinyl Chemical class 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 150000001412 amines Chemical group 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000004696 coordination complex Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000003386 piperidinyl group Chemical class 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical class 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
"BENZIMIDAZóIS QUE CONTêM MORFOLINILA, COMO INIBIDORES DA REPLICAçãO DE VìRUS SINCICIAIS RESPIRATóRIOS". A presente invenção refere-se a benzimidazóis contendo morfolinila, com atividade inibidora sobre a replicação do vírus sincicial respiratório e com a fórmula (1), uma prodroga, N-óxido, sal de adição, amina quatemária, complexo metálico e forma estereoquimicamente isomérica do mesmo, no qual G é uma ligação direta ou C~ 1-10~alcanodiila, opcionalmente substituída; R¬ 1¬ é Ar¬ 1¬ ou um heterociclo monocíclico ou bicíclico Q é R¬ 7¬, pirrolidinila, substituída com R¬ 7¬, piperidinila, substituída com R¬ 7¬ ou homopiperidinila, substituída com R¬ 7¬; um de R¬ 2a¬ e R¬ 3a¬ é escolhido de halo, C~ 1-6~ alquila, opcionalmente mono- ou polissubstituída, C~ 2-6~ alquenila, opcionalmente mono- ou polissubstituída, nitro, hidróxi, Ar¬ 2¬, N(R¬ 4a¬R¬ 4b¬), N(R¬ 4a¬R¬ 4b¬)sulfonila, N(R¬ 4a¬ R¬ 4b¬) arbonila, C~ 1-6~alquilóxi, Ar¬ 2¬C~ 1-6~alquilóxi, carboxila, C~ 1-6~alquióxi, caronila, ou -C(=Z)Ar¬ 2¬; no caso de R¬ 2a¬ ser diferente de hidrogênio, então R¬ 2b¬ é hidrogênio, C~ 1-6~alquila ou halogênio e R¬ 3b¬ é hidrogênio; o caso de R¬ 3a¬ diferente de hidrogênio, então R¬ 3b¬ é hidrogênio, C~ 1-6~alquila ou halogênio e R¬ 2b¬ é hidrogênio. A invenção refere-se, ainda, à preparação dos mesmos e a composições que compreendem esses compostos, bem como ao uso dos mesmos como medicamento.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03104810 | 2003-12-18 | ||
| US56718204P | 2004-04-30 | 2004-04-30 | |
| EP04105312 | 2004-10-26 | ||
| PCT/EP2004/053620 WO2005058871A1 (en) | 2003-12-18 | 2004-12-20 | Morpholinyl containing benzimidazoles as inhibitors of respiratory syncytial virus replication |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0417268A true BRPI0417268A (pt) | 2007-03-13 |
| BRPI0417268B1 BRPI0417268B1 (pt) | 2018-10-23 |
| BRPI0417268B8 BRPI0417268B8 (pt) | 2021-05-25 |
Family
ID=34704695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0417268A BRPI0417268B8 (pt) | 2003-12-18 | 2004-12-20 | compostos benzimidazóis que contêm morfolinila, seu uso como inibidores da replicação de vírus sinciciais respiratórios, composição que os compreende e processo para preparar os referidos compostos |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US7449463B2 (pt) |
| EP (1) | EP1697345B1 (pt) |
| JP (1) | JP4951348B2 (pt) |
| KR (1) | KR100967406B1 (pt) |
| CN (2) | CN101412709B (pt) |
| AP (1) | AP2150A (pt) |
| AR (1) | AR046959A1 (pt) |
| AT (1) | ATE388950T1 (pt) |
| AU (1) | AU2004298460B2 (pt) |
| BR (1) | BRPI0417268B8 (pt) |
| CA (1) | CA2548668C (pt) |
| CY (1) | CY1108142T1 (pt) |
| DE (1) | DE602004012448T2 (pt) |
| DK (1) | DK1697345T3 (pt) |
| EA (1) | EA009876B1 (pt) |
| EG (1) | EG25799A (pt) |
| ES (1) | ES2303653T3 (pt) |
| HR (1) | HRP20080245T3 (pt) |
| IL (1) | IL175910A (pt) |
| ME (1) | ME01042B (pt) |
| MX (1) | MXPA06007112A (pt) |
| MY (1) | MY143573A (pt) |
| NO (1) | NO339314B1 (pt) |
| NZ (1) | NZ547479A (pt) |
| PL (1) | PL1697345T3 (pt) |
| PT (1) | PT1697345E (pt) |
| RS (1) | RS50584B (pt) |
| SI (1) | SI1697345T1 (pt) |
| TW (1) | TWI351401B (pt) |
| UA (1) | UA84718C2 (pt) |
| WO (1) | WO2005058871A1 (pt) |
| ZA (1) | ZA200605894B (pt) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR046959A1 (es) * | 2003-12-18 | 2006-01-04 | Tibotec Pharm Ltd | Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio |
| TWI370820B (en) | 2005-04-27 | 2012-08-21 | Takeda Pharmaceutical | Fused heterocyclic compounds |
| MX2007016537A (es) * | 2005-06-20 | 2008-03-06 | Tibotec Pharm Ltd | 1,3-dihidro-benzoimidazol-onas 1-(2-amino-3-(alquilo sustituido)-3h-bencimidazolilmetil)-3-sustituidas con actividad sobre virus respiratorios sinciciales. |
| WO2006136562A1 (en) * | 2005-06-20 | 2006-12-28 | Tibotec Pharmaceuticals Ltd | Heterocyclylaminoalkyl substituted benzimidazoles |
| US20120148678A1 (en) | 2010-12-08 | 2012-06-14 | Advanced Technologies And Regenerative Medicine, Llc. | Sustained release of poorly water soluble active compounds |
| MY167575A (en) | 2011-10-14 | 2018-09-20 | Ambit Biosciences Corp | Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases |
| UA119050C2 (uk) * | 2013-11-11 | 2019-04-25 | Ґілеад Саєнсиз, Інк. | ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ |
| JO3637B1 (ar) | 2015-04-28 | 2020-08-27 | Janssen Sciences Ireland Uc | مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv |
| WO2017196982A1 (en) * | 2016-05-10 | 2017-11-16 | Georgia State University Research Foundation, Inc. | Bicyclic fused pyrazole derivatives for the treatment of rsv |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| EP3680241A1 (en) | 2017-03-20 | 2020-07-15 | Forma Therapeutics, Inc. | Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators |
| TW201932470A (zh) | 2017-11-29 | 2019-08-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 具有抗ｒｓｖ活性之吡唑并嘧啶 |
| AU2019216260B2 (en) | 2018-01-31 | 2023-03-02 | Janssen Sciences Ireland Unlimited Company | Cycloalkyl substituted pyrazolopyrimidines having activity against RSV |
| CA3095277A1 (en) | 2018-04-23 | 2019-10-31 | Janssen Sciences Ireland Unlimited Company | Heteroaromatic compounds having activity against rsv |
| WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| US10675274B2 (en) | 2018-09-19 | 2020-06-09 | Forma Therapeutics, Inc. | Activating pyruvate kinase R |
| GB201820751D0 (en) * | 2018-12-19 | 2019-01-30 | Bp Oil Int | Methods for preparing intermediates |
| PE20220937A1 (es) | 2019-07-22 | 2022-05-31 | Lupin Ltd | Compuestos macrociclicos como agonistas de sting y metodos y usos de los mismos |
| HUE072832T2 (hu) | 2019-09-19 | 2025-12-28 | Novo Nordisk Healthcare Ag | Piruvát kináz R-t (PKR) aktiváló készítmények |
| US12544371B2 (en) | 2020-03-20 | 2026-02-10 | Calcimedica, Inc. | Methods and compositions for treating acute lung injury and acute respiratory distress syndrome |
| US12522589B2 (en) | 2020-11-13 | 2026-01-13 | Calcimedica, Inc. | Synthesis of CRAC channel inhibitors |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| US20240352013A1 (en) * | 2021-08-13 | 2024-10-24 | Georgia State University Research Foundation, Inc. | Bicyclic fused pyrazole derivatives for the treatment of respiratory infections including rsv |
| CN119118850B (zh) * | 2023-06-13 | 2025-12-12 | 中国科学院兰州化学物理研究所 | 一种吲哚类化合物结构重整制备胺基苯乙醇类化合物的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE258928T1 (de) * | 1999-06-28 | 2004-02-15 | Janssen Pharmaceutica Nv | Respiratorisches syncytialvirus replikation inhibitoren |
| EP1418175A1 (en) * | 1999-06-28 | 2004-05-12 | Janssen Pharmaceutica N.V. | Respiratory syncytial virus replication inhibitors |
| EP1400519B1 (en) * | 1999-06-28 | 2007-03-07 | Janssen Pharmaceutica N.V. | Respiratory syncytial virus replication inhibitors |
| AR046959A1 (es) * | 2003-12-18 | 2006-01-04 | Tibotec Pharm Ltd | Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio |
| TWI356055B (en) * | 2003-12-18 | 2012-01-11 | Tibotec Pharm Ltd | Aminobenzimidazoles and benzimidazoles as inhibito |
-
2004
- 2004-12-17 AR ARP040104755A patent/AR046959A1/es active IP Right Grant
- 2004-12-20 RS RSP-2008/0266A patent/RS50584B/sr unknown
- 2004-12-20 BR BRPI0417268A patent/BRPI0417268B8/pt not_active IP Right Cessation
- 2004-12-20 CA CA2548668A patent/CA2548668C/en not_active Expired - Lifetime
- 2004-12-20 MY MYPI20045259A patent/MY143573A/en unknown
- 2004-12-20 MX MXPA06007112A patent/MXPA06007112A/es active IP Right Grant
- 2004-12-20 WO PCT/EP2004/053620 patent/WO2005058871A1/en not_active Ceased
- 2004-12-20 AT AT04817576T patent/ATE388950T1/de active
- 2004-12-20 NZ NZ547479A patent/NZ547479A/en not_active IP Right Cessation
- 2004-12-20 ES ES04817576T patent/ES2303653T3/es not_active Expired - Lifetime
- 2004-12-20 KR KR1020067014047A patent/KR100967406B1/ko not_active Expired - Fee Related
- 2004-12-20 SI SI200430732T patent/SI1697345T1/sl unknown
- 2004-12-20 AU AU2004298460A patent/AU2004298460B2/en not_active Ceased
- 2004-12-20 DE DE602004012448T patent/DE602004012448T2/de not_active Expired - Lifetime
- 2004-12-20 UA UAA200606224A patent/UA84718C2/ru unknown
- 2004-12-20 DK DK04817576T patent/DK1697345T3/da active
- 2004-12-20 PL PL04817576T patent/PL1697345T3/pl unknown
- 2004-12-20 JP JP2006544467A patent/JP4951348B2/ja not_active Expired - Fee Related
- 2004-12-20 ME MEP-2008-207A patent/ME01042B/me unknown
- 2004-12-20 PT PT04817576T patent/PT1697345E/pt unknown
- 2004-12-20 CN CN200810166056.9A patent/CN101412709B/zh not_active Expired - Lifetime
- 2004-12-20 EP EP04817576A patent/EP1697345B1/en not_active Expired - Lifetime
- 2004-12-20 EA EA200601178A patent/EA009876B1/ru unknown
- 2004-12-20 AP AP2006003640A patent/AP2150A/xx active
- 2004-12-20 CN CNA2004800378255A patent/CN1894237A/zh active Pending
- 2004-12-20 HR HR20080245T patent/HRP20080245T3/xx unknown
- 2004-12-20 US US10/563,691 patent/US7449463B2/en not_active Expired - Lifetime
- 2004-12-20 TW TW093139923A patent/TWI351401B/zh not_active IP Right Cessation
-
2006
- 2006-05-25 IL IL175910A patent/IL175910A/en active IP Right Grant
- 2006-06-14 EG EGNA2006000561 patent/EG25799A/xx active
- 2006-07-17 ZA ZA2006/05894A patent/ZA200605894B/en unknown
- 2006-07-18 NO NO20063322A patent/NO339314B1/no not_active IP Right Cessation
-
2008
- 2008-06-12 CY CY20081100633T patent/CY1108142T1/el unknown
- 2008-06-17 US US12/140,686 patent/US8883837B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0210028A (pt) | Agentes antibacterianos | |
| UY27604A1 (es) | Compuestos químicos. | |
| BR0307409A (pt) | Compostos de hidrazida de ácido 2-furanocarboxìlico, composições farmacêuticas contendo os mesmos e uso dos mesmos para preparação de um agente preventivo ou terapêutico | |
| MX2007015863A (es) | Inhibidores de esfingosina cinasa. | |
| BRPI0614524B8 (pt) | uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, e o referido composto | |
| BR0213790A (pt) | Derivados de aminobenzamida como inibidores de glicogênio sintase cinase 3beta | |
| TW200833370A (en) | Pharmaceutical composition containing low substituted hydroxypropylcellulose | |
| CR11857A (es) | Compuestos pirazolicos 436 | |
| BR0317572A (pt) | Benzoxazinas e seus derivados como inibidores de pi3ks | |
| CY1106522T1 (el) | Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο | |
| UY27592A1 (es) | Nuevo uso | |
| TW200730502A (en) | Isoquinoline aminopyrazole derivatives, their manufacture and use as pharmaceutical agents | |
| BRPI0510414A (pt) | uso de derivados de quinolina substituìdos para o tratamento de doenças micobacterianas resistentes a fármacos | |
| BR0111377A (pt) | Derivados de tiofeno úteis como agentes anticancerìgenos | |
| AU2003228770A8 (en) | Substituted pyrazolopyrimidines | |
| TW200621737A (en) | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | |
| UA84718C2 (ru) | Бензимидазолы, которые содержат морфолинил, как ингибиторы репликации респираторно-синцитиального вируса | |
| BRPI0408353A (pt) | composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto | |
| PA8575601A1 (es) | Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso | |
| SE0403171D0 (sv) | New compounds | |
| TR200301723T4 (tr) | 1,3 Dihidro-2H-indol-2 one türevleri ve bunların, arginin-vasopressin' in V1B veya V1B reseptörleri için bağ maddeleri olarak kullanımı | |
| BR0212069A (pt) | Agentes antidiabéticos orais | |
| BRPI0508107A (pt) | derivados de indazol e composições farmacêuticas contendo os mesmos | |
| BRPI0614493B8 (pt) | uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, processo para a preparação de um composto e o referido composto | |
| BRPI0417811A (pt) | aminobenzimidazóis e benzimidazóis como inibidores da replicação do vìrus sincicial respiratório |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: TIBOTEC PHARMACEUTICALS (IE) |
|
| B25D | Requested change of name of applicant approved |
Owner name: JANSSEN R AND D IRELAND (IE) |
|
| B25A | Requested transfer of rights approved |
Owner name: JANSSEN SCIENCES IRELAND UC (IE) |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/10/2018, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/12/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 19A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2754 DE 17-10-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |